CClinicalTrials.gg
CompletedNCT02473991Updated Aug 2, 2017Results posted

Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight

An observational study in Pregnancy, Fetal Macrosomia and Intrauterine Growth Restriction, sponsored by Ain Shams Maternity Hospital. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-02.

Sponsored by Ain Shams Maternity Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
395
Ages
20 Years to 30 Years
Sex
Female
01

Study summary

The aim of this prospective longitudinal study was to investigate the relationship between placental thickness during the second and third trimesters and placental and birth weights.

Read the detailed description

The investigator will make certain that the appropriate informed consent process is in place to ensure that potential research subjects, or their authorized representatives, are fully informed about the nature and objectives of the study, the potential risk and benefits of study participation, and their right as research subjects.

All laboratory specimens, evaluation forms, reports, video recordings, and other records that leave the site will not include unique personal data to maintain subject confidentiality.

All patients provided an informed written consent after they were fully instructed about the investigation.The study was approved by ethical committee of Ain Shams University.

All recruited women were observed at the 1st trimester screening at antenatal clinic and assessed for baseline demographic and obstetric data including age, parity, body mass index (BMI) and past medical events. Smoking, alcohol and drug use were also determined.

At second and third trimester (15-20 and 30-34 weeks of gestation respectively), the maternal weight, weight gain, BMI, BMI gain and data of ultrasound examination were recorded. At the time of delivery after assessment of maternal weight as mentioned above, the birth weight (in grams), fetal sex, and mode of delivery were taken.

All pregnant women underwent ultrasound evaluation of placental thickness at the time of second trimester (15-20 weeks of gestation) as well as third trimester (30-34 weeks of gestation).

All sonographic examinations were performed trans-abdominal using a Medison X4 ultrasound machine Trans abdominal4.0 megahertz (MHz) probe at The Special Care Center for Fetus Unit at Ain Shams University Maternity Hospital.

The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion as described by Hoddick et al

Each evaluation was performed by one of two experienced sonographers of our hospital with minimum inter- and intra-observer variability.

After delivery, the placenta was weighed in grams as previously described by Azpurua et al.

Fetal weight (primary objective) and neonatal status and morbidity including baby Apgar scores, fetal distress or fetal death and admission to the neonatal intensive care unit were also determined. All the examinations and data recording were performed by two senior resident physicians.(secondary objective)

02

Conditions studied

  • Pregnancy
  • Fetal Macrosomia
  • Intrauterine Growth Restriction
03

Who can participate

Ages eligible
20 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

uncomplicated pregnant women who will attend the outpatient clinic at Ain Shams University Maternity Hospital

Inclusion criteria

  1. patient Aged between 18 and 45 years.
  2. singleton viable pregnancy.
  3. non scared uterus.

Exclusion criteria

Exclusion Criteria:

  1. systemic illness (DM,Hypertension, renal disease, liver disease, sickle cell disease)
  2. known congenital fetal anomalies.
  3. multiple pregnancy.
  4. intra uterine fetal death.
  5. anatomical defect of pregnant uterus
  6. abnormally located placenta or placental anomalies
  7. morbid obesity
  8. missing records
  9. unwilling to incorporate in the study.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
395 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • Radiationultrasound

    The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion

05

What researchers measure

Primary outcomes

  1. Fetal Weight (Fetal Weight at Birth)

    Fetal weight (fetal weight at birth) (in grams)

    Time frame: 9 months

  2. Placental Thickness in Second Trimester

    placental thickness measured in millimeter

    Time frame: 15-20 weeks of gestation

  3. Placental Thickness at 3rd Trimester

    Time frame: 30-34 weeks of pregnancy

06

Results

Posted Aug 2, 2017

Participant flow

Participant flow — Overall Study
MilestonePregnant Women
Started395
Completed395
Not completed0

Outcome measures

PrimaryFetal Weight (Fetal Weight at Birth)

Fetal weight (fetal weight at birth) (in grams)

Time frame:
9 months
Reported as:
Mean · gram
Fetal Weight (Fetal Weight at Birth)
gramPregnant Women
Fetal Weight (Fetal Weight at Birth)3243 ± 402
PrimaryPlacental Thickness in Second Trimester

placental thickness measured in millimeter

Time frame:
15-20 weeks of gestation
Reported as:
Mean · millimeter
Placental Thickness in Second Trimester
millimeterPregnant Women
Placental Thickness in Second Trimester21.5 ± 2.5
Statistical analysis
  • Pregnant Women · Regression, Linear · p = <0.01
PrimaryPlacental Thickness at 3rd Trimester
Time frame:
30-34 weeks of pregnancy
Reported as:
Mean · millimeter
Placental Thickness at 3rd Trimester
millimeterPregnant Women
Placental Thickness at 3rd Trimester35.6 ± 4.1
Statistical analysis
  • Pregnant Women · Regression, Linear · p = <0.01

Adverse events

Collected over adverse event data collection was about 9 months ( time between starting antenatal care and end delivery ). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregnant Women—0/395 (0%)0/395 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pregnant Women
Mean25 ± 3
Sex: Female, Male
Sex: Female, Male(Participants)Pregnant Women
Female395
Male0
weight
weight(kg)Pregnant Women
Mean78 ± 12
Height
Height(Meter)Pregnant Women
Mean1.7 ± .07
07

Study locations

1 site
  • Ain shams faculty of medicine
    Cairo, Elabbasia, Egypt
08

References and documents

Publications

  • Azpurua H, Funai EF, Coraluzzi LM, Doherty LF, Sasson IE, Kliman M, Kliman HJ. Determination of placental weight using two-dimensional sonography and volumetric mathematic modeling. Am J Perinatol. 2010 Feb;27(2):151-5. doi: 10.1055/s-0029-1234034. Epub 2009 Aug 3. PubMed 19653142 ↗
  • Hoddick WK, Mahony BS, Callen PW, Filly RA. Placental thickness. J Ultrasound Med. 1985 Sep;4(9):479-82. doi: 10.7863/jum.1985.4.9.479. PubMed 3903201 ↗

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT02473991
Lead sponsor
Ain Shams Maternity Hospital
Collaborators
Ain Shams University
Responsible party
amr elsayed elsayed (researcher for master degree, Ain Shams Maternity Hospital) — Principal investigator
First posted
Jun 17, 2015
Start date
Mar 2015
Primary completion
Dec 2016
Completion
Jan 2017
Results posted
Aug 2, 2017
Last update
Aug 2, 2017

Study contacts

AHMED MEKLED, Professor
study director · Ain Shams University
HAYTHAM SABAA, Lecturer
study director · Ain Shams University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion